Fig 1: Sensitivity analysis evaluating the association between IGFBP7 as a categorical variable, 6 month change in LVMi, and treatment with empagliflozin 10 mg/day or matching placebo. Data presented as mean (standard deviation) or adjusted difference (95% confidence interval). IGFBP7, insulin‐like growth factor‐binding protein 7; LVMi, left ventricular mass index. ANCOVA model adjusted for baseline left ventricular mass index, sex, age, duration of type 2 diabetes, HbA1c, glucose (random), systolic blood pressure, and haemoglobin.
Fig 2: Adjusted association between 6 month change in LVMi, baseline IGFBP7, and treatment with empagliflozin 10 mg/day or matching placebo. Data are presented as mean (standard deviation). IGFBP7, insulin‐like growth factor‐binding protein 7; LVMi, left ventricular mass index. aANCOVA model adjusted for baseline left ventricular mass index, sex, age, duration of type 2 diabetes, HbA1c, glucose (random), systolic blood pressure, and haemoglobin.
Fig 3: Participant flow chart. IGFBP7, insulin like growth factor‐binding protein 7; LVMi, left ventricular mass index.
Fig 4: The concentrations of serum TIMP-2 (a), IGFBP-7 (b), TIMP-2×IGFBP-7 (c) and Ang-2 (d) between the health, SA-noAKI, and SA-AKI groups. *P < 0.05, **P < 0.01. TIMP-2 tissue inhibitor of metalloproteinase-2, IGFBP-7 insulin-like growth factor-binding protein 7, Ang-2 angiopoietin-2.
Fig 5: The ROC curves of Model 1 and Model 2 for predicting SA-AKI. Model 1: PCT, SOFA, UA; Model 2: TIMP-2×IGFBP-7, Ang-2, PCT.
Supplier Page from Abcam for Human IGFBP7 ELISA Kit